Onyx buy sets dealmaking era for Amgen
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Leading the leaders: Institutions step up with new nonprofit management offerings
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →The top five financial truths in blockbuster Amgen-Onyx deal
For sheer size and scale, Amgen’s $10.4 billion purchase of South San Francisco-based cancer drug maker Onyx Pharmaceuticals dwarfs any recent deal in the Tri-Counties. For size, let’s remember that Dole Food Co. is selling its entire self for about $1.3 billion and that Santa Barbara Bank & Trust parent Pacific Capital Bancorp, previously the Read More →
Read More →A slick solution: CLU professor creates electrostatic notes
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →In with the old: Communities find new ways to fund redevelopment
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Breeding new biotech firms: Incubator in Thousand Oaks fosters startups
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Ceres loses $9.3M, missing estimates
Thousand Oaks-based agricultural biotech firm Ceres’ third-quarter net loss widened to $9.3 million, or 38 cents per share, on revenue of $1.4 million, it said July 11. The energy crop firm attributed the higher loss to added expenses from expanding business operations in Brazil and higher-than-expected variability in how much fuel its crops can produce. Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
